Table 2 Insulin versus hypoglycaemic drugs and placebo or diet
From: Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Studies | Methodological quality: low, moderate, good (BlindingY/N) | Participants (I/C) | Treatment | Follow-up (weeks) | Inclusion criteria | Primary outcome |
|---|---|---|---|---|---|---|
Blicklé 2009 [48] | Moderate (No) | 102 (103/108) | OHD (Met/S) + Insulin Glargine/Lifestyle management | 36 weeks | [7 %; 8 %] [40y; 75y] BMI: [24;35 kg/m2] | HbA1c |
Russell Jones 2006 [49] | Good (No) | 581 (234/115/232) | OHD (Met/S) + Insulin Glargine/Liraglutide placebo/Liraglutide | 26 | [7 %; 10 %] BMI < 40 kg/m2 | HbA1c |
UKPDS 33 [13] | Good (No) | 3041 (911/1234/896) | Insulin/Chlorpropamide or glibenclamide/diet | 10 years | 25-65 years FBG 6,1–15 mmol/L | CV Morbimortality |
Good (Yes) | 1027 (414/204/204/205) | Insulin/Tolbutamide/Phenformin/placebo | 10 years | Diabete < 1 year | Mortality |